Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
Rhea-AI Summary
Biofrontera (Nasdaq: BFRI) will report fourth quarter and full year 2025 financial results after U.S. market close on Thursday, March 19, 2026. The company will host a conference call and webcast on March 19, 2026 at 10:00 a.m. ET to discuss results and provide a business update.
Dial-in numbers and a webcast link are provided for investor access.
Positive
- None.
Negative
- None.
News Market Reaction – BFRI
On the day this news was published, BFRI gained 0.73%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.7% during that session. Argus tracked a trough of -13.8% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $73K to the company's valuation, bringing the market cap to $10M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BFRI was down 4.07% while peers were mixed: SBFM up 4.50%, IMCC up 2.00%, INM down 13.00%. Moves do not indicate a unified sector trend.
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings date announcement | Neutral | -6.9% | Set Q3 2025 earnings release and conference call schedule. |
Prior earnings-date scheduling news saw a negative move of -6.9%; today’s pre-announcement weakness of -4.07% is directionally consistent.
This announcement sets the date for Biofrontera’s Q4 and full-year 2025 results following a series of material updates. Recent news included record preliminary Q4 2025 revenues of $17.0–$17.5 million and full-year revenues of $41.5–$42.0 million, multiple positive Ameluz® clinical milestones with sNDA plans, and a favorable PTAB decision against a Sun Pharma patent. At the same time, filings highlighted tight liquidity, going-concern warnings, strategic asset sales, and Nasdaq listing compliance challenges, providing important context ahead of the detailed March 19 release.
Historical Comparison
In the past 12 months, BFRI had 1 similar earnings-date announcement with an average move of -6.9%. Today’s pre-announcement move of -4.07% is directionally consistent with that history.
Market Pulse Summary
This announcement sets the schedule for Biofrontera’s Q4 and full-year 2025 earnings release and conference call on March 19, 2026. It follows record preliminary revenue ranges of $17.0–$17.5 million for Q4 and $41.5–$42.0 million for 2025, alongside tight liquidity, going-concern language, and significant strategic transactions. Investors may focus on final audited numbers, cash position, profitability trends, and updates on Ameluz® clinical and regulatory milestones during the call.
Key Terms
photodynamic therapy (pdt) medical
AI-generated analysis. Not financial advice.
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call |
| Date: | Thursday, March 19, 2026 |
| Time: | 10:00 a.m. ET |
| Conference Call: | 1-888-222-5806 (U.S.) 1-412-902-6516 (international) |
| Webcast: | Webcast – Biofrontera Inc. 4Q25 and Full Year 2025 Results Conference Call https://event.choruscall.com/mediaframe/webcast.html?webcastid=XTq1cPRZ |
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera’s commercial opportunities and the commercial success of its products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® and/or RhodoLED® XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
1 https://www.skincancer.org/skin-cancer-information/actinic-keratosis/
FAQ
When will Biofrontera (BFRI) release its Q4 and full year 2025 results?
What time is the Biofrontera (BFRI) conference call on March 19, 2026?
How can investors join the Biofrontera (BFRI) March 19, 2026 webcast?
What phone numbers can U.S. and international participants use for the Biofrontera (BFRI) call?
Will Biofrontera (BFRI) provide a business update during the March 19, 2026 call?
Where can I find the recording or replay of the Biofrontera (BFRI) March 19, 2026 presentation?
